Dr. Bonkole Johnson
Dr. Bonkole Johnson’s research focus is on the neuropsychopharmacology of addiction. His work integrates the neuroscience and behavioural aspects of addiction medicine with the goal of formulating a more thorough understanding of the basis of drug-seeking behaviour and developing effective treatments. Central to his research is the role of and interaction between midbrain monoamine systems with a focus on serotonin, gamma-aminobutyric acid(GABA)/glutamate and dopamine.
Johnson’s current research involves clinical trials and human laboratory studies, and includes neuroimaging and molecular genetics. He now incorporates neuroimaging evaluations into his drug interaction studies to identify the site-specific effects of abused drugs and to evaluate the effectiveness of potential medications for the treatment of addiction. Current studies include a clinical trial aimed at determining the effectiveness of ondansetron, a serotonin-3 antagonist, for the treatment of subtypes of alcoholics, as well as a human laboratory project trying to elucidate the effects of naltrexoneand acamprosate on hepatic and renal function in alcohol-dependent individuals.